Susquehanna Fundamental Investments LLC Takes $746,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

Susquehanna Fundamental Investments LLC bought a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 237,465 shares of the company's stock, valued at approximately $746,000. Susquehanna Fundamental Investments LLC owned about 0.24% of Acelyrin at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its holdings in shares of Acelyrin by 23.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,872,124 shares of the company's stock worth $40,419,000 after purchasing an additional 2,440,278 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Acelyrin during the 4th quarter valued at $36,000. Dimensional Fund Advisors LP bought a new position in shares of Acelyrin during the 4th quarter worth $371,000. XTX Topco Ltd purchased a new stake in Acelyrin in the 4th quarter worth about $33,000. Finally, Barclays PLC raised its stake in Acelyrin by 21.0% in the 4th quarter. Barclays PLC now owns 116,644 shares of the company's stock valued at $366,000 after acquiring an additional 20,236 shares during the period. 87.31% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Mina Kim sold 17,986 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares of the company's stock, valued at $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 13.60% of the company's stock.

Acelyrin Price Performance

NASDAQ:SLRN traded up $0.01 on Thursday, reaching $2.43. 148,718 shares of the company's stock were exchanged, compared to its average volume of 1,200,683. The stock has a fifty day simple moving average of $2.46 and a 200-day simple moving average of $3.19. Acelyrin, Inc. has a 52 week low of $1.85 and a 52 week high of $7.25. The firm has a market cap of $245.20 million, a price-to-earnings ratio of -0.99 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.07. As a group, sell-side analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.